G6PD rs1050829: What Your Genotype Means
The rs1050829 variant is a single-nucleotide polymorphism located in the G6PD gene on the X chromosome, widely known in medical genetics as defining the G6PD A (or A+) allele. While rs1050829 by itself causes little to no clinically significant reduction in glucose-6-phosphate dehydrogenase activity, it serves as the essential genetic background for compound variants that cause enzyme deficiency. Understanding this variant provides key insights into erythrocyte biochemistry, malaria evolutionary history, and pharmacogenomics.
What each genotype means
Normal enzyme activity
This genotype represents the G6PD Type B version of the gene, which is considered the reference or normal sequence. Individuals with this profile typically maintain standard glucose-6-phosphate dehydrogenase enzyme function and do not show the reduced activity associated with the G allele.
This is the most common genotype globally, particularly in populations outside of regions where the G allele is prevalent.
Intermediate enzyme activity
This genotype, often referred to as G6PD Type A/B, involves one copy of the reference allele and one copy of the G allele. While the G allele (A376G) is associated with reduced enzyme production, this heterozygous state is often considered clinically benign on its own, though it may be a component of more complex deficiency profiles when combined with other mutations.
This genotype is frequently observed in populations with African ancestry where the G allele is common.
Reduced enzyme activity
This genotype, known as G6PD Type A, is associated with reduced production of the G6PD enzyme. While often considered possibly benign in isolation, it is a key genetic marker that, when combined with other specific mutations like rs1050828, can lead to G6PD deficiency; please discuss any concerns regarding medication sensitivity or clinical symptoms with your healthcare provider.
This genotype is predominantly found in individuals of African ancestry and is less common in other global populations.
Genetic Location and Biochemical Context
The single-nucleotide polymorphism rs1050829 sits in the G6PD gene on the X chromosome at position c.376A>G (coding sequence) and corresponds to an Asn126Asp (p.Asn126Asp, or historically designated Asn142Asp depending on transcript isoform) amino acid change according to [dbSNP](https://www.ncbi.nlm.nih.gov/snp/rs1050829). Because G6PD is an X-linked gene, biological males possess a single copy (hemizygous), while biological females carry two copies (homozygous or heterozygous). G6PD encodes the rate-limiting enzyme in the pentose phosphate pathway, responsible for producing NADPH. Red blood cells rely almost entirely on NADPH generated by G6PD to regenerate reduced glutathione, a vital intracellular antioxidant that neutralizes reactive oxygen species and safeguards hemoglobin from oxidative precipitation.
The G6PD A+ Allele and Disease Association
In isolation, the rs1050829 G (or C on the reverse strand) variant denotes the G6PD A (often termed G6PD A+) form, retaining approximately 85% to 100% of normal enzymatic activity as detailed in [MedlinePlus Genetics](https://medlineplus.gov/genetics/gene/g6pd/). Clinically, the variant by itself is generally classified as benign or a neutral polymorphic trait. However, rs1050829 is clinically critical because it forms the baseline haplotype for G6PD A-. When rs1050829 co-occurs in cis with a secondary deleterious variant—most commonly rs1050828 (c.202G>A)—the resulting compound haplotype leads to an unstable enzyme with residual activity dropped to 10–20%, predisposing individuals to acute hemolytic anemia upon oxidative challenge.
Pharmacogenomics and Oxidative Triggers
G6PD deficiency makes erythrocytes susceptible to acute hemolysis when exposed to triggers like fava beans, severe systemic infections, or oxidative medications such as rasburicase, primaquine, and dapsone, as cataloged by [PharmGKB](https://www.pharmgkb.org/gene/PA28568). Isolated rs1050829 carriers do not show elevated hemolytic risk under standard circumstances because their baseline enzyme stability remains adequate. However, because rs1050829 is frequently present alongside other mutations in G6PD deficiency panels, full-gene sequencing or enzymatic activity assays are recommended before assuming normal enzyme status. Individuals considering oxidative medications must consult a physician or pharmacist rather than relying on direct-to-consumer genotyping of a single variant.
Population Distribution and Evolutionary Significance
The rs1050829 alternative allele is exceptionally common in populations of African descent, with allele frequencies typically ranging between 10% and 40% across sub-Saharan Africa according to population surveys published in [PMC7302299](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302299). In contrast, the variant is observed at very low frequencies among populations of European and East Asian descent. Evolutionary geneticists view the high prevalence of rs1050829 as a historical marker of balancing selection in malaria-endemic regions, where related G6PD variations provide partial selective protection against severe falciparum malaria without conferring substantial health consequences on their own.
Clinical Interpretation: What You Can and Cannot Do
Discovering an rs1050829 variant in personal genomic data indicates the presence of the G6PD A allele, but it cannot independently diagnose or rule out G6PD enzyme deficiency. In females, random X-chromosome inactivation creates mosaicism, meaning genotype alone cannot precisely predict systemic enzyme levels. If you suspect an adverse drug reaction or family history of hemolysis, clinical laboratories rely on quantitative G6PD enzymatic activity assays rather than isolated SNP profiling. Always discuss these genetic results and medication management directly with a qualified healthcare provider or clinical geneticist.
How common is this variant?
The rs1050829 alternate allele (c.376A>G) occurs at frequencies of roughly 10% to 40% across sub-Saharan African populations, while remaining rare or virtually absent in unadmixed non-African populations.
Frequently asked questions
Does having the rs1050829 variant mean I have G6PD deficiency?
No, having rs1050829 alone (the G6PD A+ allele) generally retains normal or near-normal enzyme function. G6PD deficiency typically requires a second co-inherited mutation, such as rs1050828, which creates the deficient G6PD A- haplotype.
Can I eat fava beans or take oxidative medications if I carry rs1050829?
Carriers of isolated rs1050829 usually have sufficient baseline enzyme levels to tolerate common dietary and pharmacological exposures. However, because genetic testing often misses secondary mutations, any medication dosing or dietary restrictions should be reviewed with your doctor or pharmacist based on direct G6PD enzyme activity testing.
Why does rs1050829 affect males and females differently?
The G6PD gene is located on the X chromosome, meaning biological males have only one copy and biological females have two. Females undergo random X-inactivation in their cells, resulting in a mosaic pattern of enzyme activity that moderates the functional expression of variants.
Why is the rs1050829 variant so common in certain ancestries?
The variant is predominantly found in people of sub-Saharan African ancestry due to evolutionary selection. In malaria-endemic regions, variations within the G6PD gene have historically provided partial protective advantages against severe malaria infection.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1050829?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in G6PD
Coding variant associated with G6PD deficiency and susceptibility to acute hemolytic anemia upon oxidative stress or exposure to hemolytic drugs.
Causes the A- variant of G6PD deficiency, common in African populations.
Causes G6PD deficiency and favism risk in Mediterranean populations.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia upon exposure to certain medications or fava beans.
This variant is a known genetic contributor to G6PD deficiency, impacting drug metabolism and sensitivity to oxidative stress.
This variant is associated with G6PD deficiency, which can lead to hemolytic anemia when exposed to certain medications or stressors.